Lung Cancer
Conditions
Interventions
Pathological Response Group (Cohort A):None
Progressive Advanced Lung Cancer Group (Cohort B):None
Non-Progressive Advanced Lung Cancer Group (Cohort B):None
Non-pathological response Group (Cohort A):None
Sponsors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Age between 18 and 80 years; 2.Patients with early-stage lung cancer who underwent radical pulmonary resection after neoadjuvant chemo-immunotherapy, OR patients with immune-related lung cancer receiving systemic therapy based on immune checkpoint inhibitors; 3.Availability of baseline imaging data suitable for analysis within 4 weeks prior to initiation of neoadjuvant or immunotherapy; 4.Complete clinical records with accessible key information on survival status and disease progression.
Exclusion criteria
Exclusion criteria: 1.Prior receipt of any systemic anticancer therapy targeting the current lung cancer (including chemotherapy, targeted therapy, immunotherapy, etc.), where immunotherapy was administered only as adjuvant treatment or in a short-term trial setting; 2.Concurrent presence of other active malignant tumors; 3.Any condition deemed by the investigator to render the patient unsuitable for participation in this study (e.g., psychiatric disorders, poor compliance, etc.).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pathological Complete Response, pCR;Progression-free survival;Major Pathological Response, MPR;overall survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease control rate;Objective remission rate; | — |
Countries
China
Contacts
Public ContactYANG JIN
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Outcome results
None listed